GlassScriptPhysician profile
Christopher C Whitney
NPI 1275025462
$3,050.74
in general payments reported to CMS, 2019-2025
13 companies · $589 in 2025
The $589 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $843 · 2023: $1,055 · 2024: $449 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,092.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $678.05 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $571.52 | 2021-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $385.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $322.93 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $295.01 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $256.29 | 2022 | |
| Dexcom, INC. | $207.13 | 2022-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $130.83 | 2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $101.61 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $48.41 | 2024 | Voquezna |
| Boston Scientific Corporation | $20.80 | 2025 | Spyglass Discover |
| Phadia US INC. | $18.70 | 2022 | |
| Amgen INC. | $14.29 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Whitney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.